rosuvastatin liposomal (YN001) / Inno Medicine - LARVOL DELTA

YN001-004 in Patients With Coronary Atherosclerosis in Australia (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Beijing Inno Medicine Co., Ltd. | N=12 ➔ 24 | Trial completion date: Sep 2025 ➔ Jun 2026 | Trial primary completion date: Sep 2025 ➔ Jun 2026

Enrollment change • Trial completion date • Trial primary completion date • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease

Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Beijing Inno Medicine Co., Ltd.

New P2 trial • Atherosclerosis • Cardiovascular • CNS Disorders • Erectile Dysfunction • Vascular Neurology

Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Beijing Inno Medicine Co., Ltd.

New P1 trial • Atherosclerosis • Cardiovascular • CNS Disorders • Vascular Neurology

A Pharmacokinetic Study of YN001 in Healthy Participants (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Beijing Inno Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open

A Pharmacokinetic Study of YN001 in Healthy Participants (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Beijing Inno Medicine Co., Ltd.

New P1 trial

Active-target liposomal drug shows significant atherosclerotic plaque regression effect: a proof-of-concept phase 1b/2a clinical trial (ESC-WCC 2025) - "Conclusion YN001 showed promising effectiveness in atherosclerotic plaque regression and stabilization in this proof-of-concept Phase 1b/2a clinical trial. Further results from the full study are awaited."

Clinical • P1/2 data • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease

YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis (clinicaltrials.gov) - P1/2 | N=144 | Completed | Sponsor: Beijing Inno Medicine Co., Ltd. | Recruiting ➔ Completed

Trial completion • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease

YN001-004 in Patients With Coronary Atherosclerosis in Australia (clinicaltrials.gov) - P2 | N=12 | Recruiting | Sponsor: Beijing Inno Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease

YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis (clinicaltrials.gov) - P1/2 | N=130 | Recruiting | Sponsor: Beijing Inno Medicine Co., Ltd. | Trial primary completion date: Dec 2024 ➔ Apr 2025

Trial primary completion date • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease

YN001-004 in Patients With Coronary Atherosclerosis in Australia (clinicaltrials.gov) - P2 | N=12 | Not yet recruiting | Sponsor: Beijing Inno Medicine Co., Ltd.

New P2 trial • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia

A First-in-human Study of YN001 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=64 | Completed | Sponsor: Beijing Inno Medicine Co., Ltd. | Recruiting ➔ Completed

Trial completion • Cardiovascular

YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis (clinicaltrials.gov) - P1/2 | N=130 | Recruiting | Sponsor: Beijing Inno Medicine Co., Ltd. | Trial completion date: Nov 2024 ➔ Apr 2025

Trial completion date • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia

A First-in-human Study of YN001 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=89 | Recruiting | Sponsor: Beijing Inno Medicine Co., Ltd. | Trial completion date: Apr 2024 ➔ Aug 2024 | Trial primary completion date: Apr 2024 ➔ Aug 2024

Trial completion date • Trial primary completion date • Cardiovascular

YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis (clinicaltrials.gov) - P1/2 | N=130 | Recruiting | Sponsor: Beijing Inno Medicine Co., Ltd. | Phase classification: P1 ➔ P1/2

Phase classification • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia

A First-in-human Study of YN001 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=89 | Recruiting | Sponsor: Beijing Inno Medicine Co., Ltd. | Trial completion date: Nov 2023 ➔ Apr 2024 | Trial primary completion date: Nov 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • Cardiovascular

YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis (clinicaltrials.gov) - P1 | N=128 | Recruiting | Sponsor: Beijing Inno Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia

YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis (clinicaltrials.gov) - P1 | N=128 | Not yet recruiting | Sponsor: Beijing Inno Medicine Co., Ltd.

New P1 trial • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia